MX2019009909A - Composiciones farmaceuticas para terapia de combinacion. - Google Patents

Composiciones farmaceuticas para terapia de combinacion.

Info

Publication number
MX2019009909A
MX2019009909A MX2019009909A MX2019009909A MX2019009909A MX 2019009909 A MX2019009909 A MX 2019009909A MX 2019009909 A MX2019009909 A MX 2019009909A MX 2019009909 A MX2019009909 A MX 2019009909A MX 2019009909 A MX2019009909 A MX 2019009909A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
combination therapy
combination
diseases
treatment
Prior art date
Application number
MX2019009909A
Other languages
English (en)
Inventor
Noel Benoît
Descamps Emeline
Walczak Robert
Belanger Carole
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of MX2019009909A publication Critical patent/MX2019009909A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una combinación de principios activos para su uso en el tratamiento de enfermedades.
MX2019009909A 2017-02-24 2018-02-23 Composiciones farmaceuticas para terapia de combinacion. MX2019009909A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305213 2017-02-24
PCT/EP2018/054588 WO2018154081A1 (en) 2017-02-24 2018-02-23 Pharmaceutical compositions for combination therapy

Publications (1)

Publication Number Publication Date
MX2019009909A true MX2019009909A (es) 2019-10-14

Family

ID=58231557

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009909A MX2019009909A (es) 2017-02-24 2018-02-23 Composiciones farmaceuticas para terapia de combinacion.

Country Status (14)

Country Link
US (1) US11590108B2 (es)
EP (1) EP3585384A1 (es)
JP (1) JP2020510651A (es)
KR (1) KR102633249B1 (es)
CN (1) CN110418641A (es)
AU (1) AU2018223976B2 (es)
BR (1) BR112019017314A2 (es)
CA (1) CA3051977A1 (es)
EA (1) EA201991990A1 (es)
IL (1) IL268708B (es)
MX (1) MX2019009909A (es)
PH (1) PH12019501820A1 (es)
SG (1) SG11201907084VA (es)
WO (1) WO2018154081A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4233910A3 (en) * 2016-03-31 2024-01-17 Genfit Methods of treatment of cholestatic diseases
US12053445B2 (en) * 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2206702T3 (da) 2001-08-08 2012-02-13 Tobira Therapeutics Inc Bicyklisk forbindelse, fremstilling og anvendelse deraf
FR2841900B1 (fr) 2002-07-08 2007-03-02 Genfit S A Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
KR101962209B1 (ko) * 2009-11-26 2019-03-26 장피트 간 질환 치료를 위한 1,3-디페닐프로프-2-엔-1-온 유도체의 용도
JP6217938B2 (ja) * 2011-10-28 2017-10-25 ルメナ ファーマシューティカルズ エルエルシー 小児の胆汁うっ滞性肝疾患の処置のための胆汁酸再循環阻害剤
SG11201607859SA (en) * 2014-03-21 2016-10-28 Tobira Therapeutics Inc Cenicriviroc for the treatment of fibrosis
RU2723559C2 (ru) * 2014-09-12 2020-06-16 Тобира Терапьютикс, Инк. Комбинированная терапия с применением препарата ценикривирок для лечения фиброза
JP2018532720A (ja) 2015-09-16 2018-11-08 トビラ セラピューティクス， インコーポレイテッド 線維症の治療のためのセニクリビロック併用療法
EP4233910A3 (en) 2016-03-31 2024-01-17 Genfit Methods of treatment of cholestatic diseases
CN109152760B (zh) 2016-04-11 2022-09-23 基恩菲特公司 胆汁淤积性和纤维化疾病的治疗方法
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
SG11201906041QA (en) 2017-01-27 2019-08-27 Genfit Pharmaceutical compositions for combination therapy

Also Published As

Publication number Publication date
KR20190119097A (ko) 2019-10-21
SG11201907084VA (en) 2019-09-27
AU2018223976B2 (en) 2023-08-17
CN110418641A (zh) 2019-11-05
EP3585384A1 (en) 2020-01-01
US11590108B2 (en) 2023-02-28
CA3051977A1 (en) 2018-08-30
AU2018223976A1 (en) 2019-09-05
IL268708A (en) 2019-10-31
IL268708B (en) 2022-05-01
PH12019501820A1 (en) 2020-09-14
US20190388394A1 (en) 2019-12-26
BR112019017314A2 (pt) 2020-04-14
WO2018154081A1 (en) 2018-08-30
JP2020510651A (ja) 2020-04-09
EA201991990A1 (ru) 2020-04-07
KR102633249B1 (ko) 2024-02-02

Similar Documents

Publication Publication Date Title
MX2020001513A (es) Agentes de union a clec9a y su uso.
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
MX2017006437A (es) Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12018502161A1 (en) Methods of treatment for cholestatic and fibrotic diseases
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
MX2019010218A (es) Derivados de pirazol como inhibidores de bromodominio.
PH12018500682A1 (en) Oxa-diazaspiro compounds having activity against pain
IN2013MU03118A (es)
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
MX2018004774A (es) Derivados de morfolina sustituidos que tienen actividad contra el dolor.
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
EA201991866A1 (ru) Комбинированная терапия
MX2018000418A (es) Derivados de amida que tienen actividad multimodal contra el dolor.
MX2016016061A (es) 2,2,2-trifluoroetil-tiadiazinas.
MX2018004776A (es) Compuestos oxaazaespiricos con actividad contral el dolor.
TR201716203A1 (tr) Yeni umeklidinyum formülasyonları.